Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
about
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolatesAntimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusActivity of and resistance to moxifloxacin in Staphylococcus aureus.Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus.Novel agents for the treatment of resistant Gram-positive infections.Efflux-mediated antimicrobial resistance.QSAR based therapeutic management of M. tuberculosis.ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniaeQuinolone resistance due to reduced target enzyme expressionActivities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr.Quinolones: action and resistance updated.In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compoundsMechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones.Efficient Synthesis of the 2-amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-c]pyrimidine-1,3-dione core ring system.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.Topoisomerases as anticancer targets.
P2860
Q33770013-60F2379C-6E92-4C54-B3D7-8D5BA5A7EBF9Q33836603-B08FD972-FD4B-4C7F-B46D-8FF5F42C4DEFQ34139244-A503EA97-872B-4259-8F2B-0FAD89C0180AQ34228402-933FB635-7350-49A3-8892-1ABDC35365C2Q34352135-B75B1A3C-800D-4B9C-AFA2-79832E9D9D06Q34447679-CB625E88-FAD6-4B47-843E-E1F5EB70B50EQ34725095-E6FD1FE1-ECFE-4F92-A72E-1C963B6C2651Q34885313-B58128E9-BD75-450C-891C-AC5CC3603BA7Q34977654-0148B692-D230-413E-8826-2D06A0DC7C71Q35056042-80F4B850-C865-4CA6-BC69-916E637A73F4Q36138147-6D2C8EA2-F5E0-4ED2-BDD8-AE1E921F6721Q36359056-64F1120D-3558-48B9-8385-1797972BB26AQ36474350-8E59BEEB-59F5-46A0-B937-9D5BEF13C306Q37062733-43ED58D2-7D38-4225-9ECF-6D0B8D26DA1DQ37121180-73DCD28F-528A-4A94-8C1C-F6F6044FCB30Q37595559-39932E72-86F0-4BEA-AE3A-8A69BB444C48Q39686067-398A1260-7751-49D2-B3F8-F0013704A808Q39792656-A555EBDC-CE09-478E-ABB8-70C2A28FB244Q40130516-E058A0F5-4EF3-4158-A5D1-D59F381C658CQ40130597-6872CA62-A841-4B34-A72D-14934B8032C6Q41687386-CA2E762B-40C5-4C81-A283-E244612C535CQ41822811-C099B240-87E6-41A0-9AC9-A3D92DD3C1F9Q41925162-76E8BFD3-0A63-42AE-8EFA-1C4C11B0DC70Q42183775-8A83A70D-9BCA-4469-B90B-6010B440C4FEQ43193286-AF90C0A4-EAF9-43AC-AC0E-751362398612Q43251107-A2962B9E-DD5B-4EAA-9537-644954E35CCFQ49832269-5E9334E6-4D30-4CDB-8CD9-4574F794837F
P2860
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@ast
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@en
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@nl
type
label
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@ast
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@en
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@nl
prefLabel
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@ast
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@en
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@nl
P2093
P2860
P1476
Dual targeting of DNA gyrase a ...... ME), a new desfluoroquinolone.
@en
P2093
David C Hooper
Dilek Ince
L Christine Silver
Xiamei Zhang
P2860
P304
P356
10.1128/AAC.46.11.3370-3380.2002
P407
P577
2002-11-01T00:00:00Z